Clinical trial · Interventional
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
Superiority of Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The hypothesis of the study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC. Characters of the patients: * list item one: 168 patients, median age 48 years (range 16-75 years） proven rT1-2 NPC were diagnosed * list item two: Treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT Combined 3D-CRT or IMRT). * list item three: Median time to recurrence was 30 months (range 1-180months). The median follow-up time was 28 months (range, 4-135 months).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- recurrent T1-2 NPC,no treatment
- description
- 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
- interventionNames
- Radiation: 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
Primary outcomes (1)
- measure
- all cause mortality
- timeFrame
- thirteen years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * recurrent T1-2 nasopharyngeal carcinoma patients Exclusion Criteria: * non recurrent T1-2 nasopharyngeal carcinoma patients
References
Publications (0)
Data not yet available